On the other hand, in pancreatic cancer with low RRM1, there was a trend toward a benefit from additional postoperative adjuvant chemotherapy comparing to no adjuvant group, although the difference was not statistically significant (Fig 2D). Here, RRM1 is linked to pancreatic neoplasm.